Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth

Leukemia

Volumn 10, Issue 12, 1996, Pages 1980-1989

  Williams, S A ^a   Chang, L ^a   Buzby, J S ^a   Suen, Y ^a   Cairo, M S ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Antisense ODN; Burkitt's lymphoma; Cationic lipids; Lipofectamine

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CATION; DRUG VEHICLE; LIPID;

ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DAUDI CELL; DRUG UPTAKE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOMA CELL LINE; ONCOGENE C MYC; PRIORITY JOURNAL;

EID: 0030474873     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Magrath I. The pathogenesis of Burkitt's lymphoma. Adv Cancer Res 1990; 55: 133-270.
2. Harel-Bellan A, Ferris DK, Vinocour M, Holt JT, Farrar WL. Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol 1988; 140: 2431-2435.
3. Holt J, Redner R, Nienhuis A. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol 1988; 8: 963-973.
4. Wickstrom EL, Bacon T, Gonzalez A, Freeman D, Lyman G, Wickstron E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA 1988; 85: 1028-1032.
5. McManaway ME, Neckers LM, Loke SL, Al-Nassar AA, Redner RL, Shiramizu BT, Goldschmidts WL, Huber BE, Bhatia K, Magrath IT. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808-811.
6. Williams S, Gillian E, Suen Y, Ishizawa L, Cairo MS. C-myc antisense oligodeoxynucleotides reduce viability, proliferation, and c-myc protein expression in a human leukemia cell line: therapeutic implications. AACR 1994; 35: 616 (Abstr).
7. Gillan E, Suen Y, Knoppel E, Buzby J, Cairo MS. C-myc antisense (AS) oligodeoxynucleotides reduce viability and proliferation in c-myc cancer. AACR Pro 1993; 34: 2315a (Abstr).
8. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984; 4: 2486-2497.
9. Degols G, Leonetti JP, Mechti N, Lebleu B. Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res 1991; 19: 945-948.
10. Leonetti JP, Machy P, Degols C, Lebleu B, Leserman L. Antibodytargeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA 1990; 87: 2448-2451.
11. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci 1987; 84: 7413-7417.
12. Caplen NJ, Gao X, Hayes P, Elaswarapu R, Fisher G, Kinrade E, Chakera A, Schorr J, Hughes B, Dorin J, Porteous DJ, Alton E, Geddes DM, Coutelle C, Williamson R, Huang L, Gilchrist C. Gene therapy for cystic fibrosis in humans by lipsome-mediated DNA transfer: the production of resources and the regulatory process. Gene Therapy 1994; 1: 139-147.
13. Cowens JW, Creaven PJ, Greco WR, Brenner DE, Tung Y, Ostro M, Pilkiewicz F, Ginsberg R, Petrelli N. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796-2802.
14. Colige A, Sokilov BP, Nugent P, Baserga R, Prockop DJ. Use of an antisense oligonucleotide to inhibit expression of a mutated human procollagen gene (COL1A1) in transfected mouse 3T3 cells. Biochemistry 1993; 32: 7-11.
15. Wagner RW, Matteucci MD, Lewis JG, Gutierrez AJ, Moulds C, Froehler BC. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 1993; 260: 1510-1513.
16. Bennett CF, Chiang MY, Chan H, Shoemaker JE, Mirabelli CK. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023-1033.
17. Capaccioli S, DiPasquale G, Mini E, Mazzei T, Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 1993; 197: 818-825.
18. Neckers L, Whitesell L, Rosolen A, Geselowitz DA. Antisense inhibition of oncogene expression. Crit Rev Oncogen 1992; 3: 175.
19. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression, a review. Cancer Res 1988; 48: 2659-2668.
20. Stein C, Subasinghe C, Shinozuka K, Cohen J. Physico-chemical properties of phosphorothioate oligodeoxynucleotiodes. Nucleic Acids Res 1988; 16: 3209-3221.
21. Furdon PJ, Dominski Z, Kole R. RNase H cleavage of RNA hybridized to oligonucleotides containing methylphosphonate, phosphorothioate and phosphodiester bonds. Nucleic Acids Res 1989; 17: 9193-9204.
22. Bacon TA, Wickstron E. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: Maximum efficacy at the 5′ cap region. Oncogene Res 1991; 6: 13-19.
23. Magrath I, Jain V, Bhatia K. Epstein-Barr virus and Burkitt's lymphoma. Cancer Biol 1992; 3: 285-295.
24. Shiramizu B, Barriga F, Neequaye J, Jafri A, Dalla-Favera R, Neri A, Guttierez M, Levine P, Magrath I. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991; 77: 1516-1526.
25. + cord blood. Pediatr Res 1992; 32: 277-281.
26. Kaltenbachm JP, Kaltenback MH, Lyons WB. Nigrosin as a dye for differentiating live and dead ascites cells, Exp Cell Res 1958; 15: 112-117.
27. Biro S, Fu Y-M, Yu Z-X, Epstein S. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Proc Natl Acad Sci USA 1993; 90: 654-658.
28. Korsmeyer SJ. Bcl-2: an antidote to programmed cell death. Cancer Surv 1992; 15: 105-118.
29. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
30. Cotter FE, Corbo M, Raynaud F, Orr R, Pocock C, Bryan B, Harper M, Webb A, Clarke P, Judson I, Cunningham D. BCL-2 antisense therapy in lymphoma: in vitro and in vivo mechanisms, efficacy, pharmakokinetic and toxicity studies. Ann Oncol 1996; 7: 100 (Abstr.).
31. de Fabritiis P, Amadori S, Petti MC, Mancini M, Montefusco E, Picardi A, Geiser T, Campbell K, Calabretta B, Mandelli F. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not prevent haematologic reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9: 662-664.
32. Webb A, Cunningham D, Cotter F, Hill M, Clarke P, de Stefano F, Viner C, Prendeville J, Rahal S, Dziewanowska Z. Phase I BCL-2 antisense trial: preliminary results. Ann Oncol 1996; 7: 101 (Abstr.).
33. ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce C. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt's lymphoma. Science 1983; 222: 390-393.
34. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res 1986; 47: 189-234.
35. Hayday AC, Gillies SD, Saito H, Wood C, Wiman D, Hayward WS, Tonegawa S. Activation of a translocated human c-myc gene by an enhancer in the immunoglobulin heavy-chain locus. Nature 1984; 307: 334-340.
36. Nishikura K, ar-Rushdi A, Erikson J, Watt R, Rovera G, Croce CM. Differential expression of the normal and of the translocated human c-myc oncogenes in B cells. Proc Natl Acad Sci USA 1983; 80: 4822-4826.
37. Wu-Pong S, Weiss TL, Hunt CA. Antisense c-myc oligodeoxyribonucleotide cellular uptake. Pharmacol Res 1992; 9: 1010-1017.
38. Wickstrom EL, Bacon TA, Gonzalez A, Lyman GH, Wickstrom E. Anti-c-myc DNA increases differentiation and decreases colony formation by HL-60 cells. In Vitro Cell Devel Biol 1989; 24: 297-302.
39. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-1012.
40. Pierga JY, Magdelenat H. Applications of antisense oligonucleotides in oncology. Cell Mol Biol 1994; 40: 237-261.
41. Giles RV, Spiller DG, Tidd DM. Detection of ribonuclease H generated mRNA fragments in human leukaemia cells following reversible membrane permeabilization in the presence of antisence oligodeoxynucleotides. Antisense Res Dev 1995; 5: 21.
42. 3H-thymidine incorporation are related to position of thymidine residues in oligodeoxynucleotides. Exp Hematol 1994; 22: 384-387.
43. Gao W, Man F-S, Storm C, Egan W, Cheng Y-C. Phosphorothioate oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol Pharmacol 1992; 41: 223-229.
44. Majumdar D, Stein C, Cohen J, Broder S, Wilson S. HIV reverse transcriptase stepwise mechanism: phosphorothioate oligodeoxynucleotide as primer. Biochemistry 1989; 28: 1340-1346.
45. Yaswen P, Stampfer MR, Chosh K, Cohen JS. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelia cells. Antisense Res Devel 1993; 3: 67-77.
46. Cordon J, Knox K, Gregory CD. Regulation of survival in normal and neoplastic B lymphocytes. Leukemia 1993; 7: S5-S9.
47. Ghetie M-A, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G, Amlot P, Vitetta ES, Thorpe PE. Evaluation of ricin a chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988; 48: 2610-2617.
48. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
49. Gulati SC, Shank B, Black P, Yopp J, Koziner B, Straus D, Filippa D, Kempin S, Castro-Malaspina H, Cunningham I, Berman E, Coleman M, Langleben A, Colvin OM, Fuks Z, O'Reilly R, Clarkson B. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303-1313.
50. Uckun FM, Stong RC, Youle RJ, Vallera DA. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. J Immunol 1985; 134: 3504-3515.
51. Uckun FM, Kersey JH, Haake R, Weisdorf D, Ramsay NK. Autologous bone marrow transplantation in high-risk remission B-lin-eage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (Ba-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 1992; 79: 1094-1104.
52. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blattler WA, Epstein CL, Nadler LM. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993; 81: 2263-2271.
53. Uckun FM, Kersey JH, Vallera DA, Ledbetter JA, Weisdorf D, Myers DE, Haake R, Ramsay N. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723-1733.